Advertisement
UK markets closed
  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     
  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     
  • AIM

    745.67
    +0.38 (+0.05%)
     
  • GBP/EUR

    1.1613
    -0.0070 (-0.60%)
     
  • GBP/USD

    1.2370
    -0.0069 (-0.55%)
     
  • Bitcoin GBP

    51,897.45
    +912.17 (+1.79%)
     
  • CMC Crypto 200

    1,382.03
    +69.41 (+5.29%)
     
  • S&P 500

    4,961.21
    -49.91 (-1.00%)
     
  • DOW

    37,906.71
    +131.33 (+0.35%)
     
  • CRUDE OIL

    83.17
    +0.44 (+0.53%)
     
  • GOLD FUTURES

    2,410.10
    +12.10 (+0.50%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     

Blueprint Medicines Shows Market Leadership With Jump To 93 RS Rating

Blueprint Medicines Shows Market Leadership With Jump To 93 RS Rating

Blueprint Medicines (BPMC) saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 90 to 93. [ibd-display-video id=2385970 width=50 float=left autostart=true] When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.